Figure 4.

Zolbetuximab alone and in combination with gemcitabine prevents lung metastasis formation in IV mouse xenograft models.

Mice were inoculated by IV injection of 2 × 10⁶ (a) SUIT-2~ CLDN18.2 or (b) Patu 8988S human PC cells into the tail vein of female Hsd:Athymic Nude-Foxn1^nu mice. Alternating IV/IP injections with 200 µg zolbetuximab or isotype (with 100 mg/kg IP gemcitabine in combination studies) were initiated on Day 3 post-graft or 2 weeks after tumor injection and given twice per week. Mice were euthanized at different time points, or after the animals in the control group showed clear physiologic signs of metastatic disease.(a) Human DNA content with zolbetuximab (200 μg) or isotype.(b) Human DNA content (left panel) and MHC-I on lung surface (right panel) with or without zolbetuximab + Gem (zolbetuximab 200 μg + Gem 100 mg/kg semi-weekly for 4 weeks or with 200 μg isotype control antibody + 100 mg/kg Gem semi-weekly). Data are mean ± SEM. **P < .01based on Mann–Whitney U-test (two-tailed). MHC-I staining was performed with anti-human MHC-I (EPR1394Y) antibody.Abbreviations: Gem, gemcitabine; IHC, immunohistochemistry; IP, intraperitoneal; IV, intravenous; MHC, major histocompatibility complex; SEM, standard error of the mean.